Eiken ChemicalEIKEN CHEMICAL CO.,LTD.4549東証プライム医薬品FY ending Mar 2026, consolidated, J-GAAP
Out of every ¥100 of sales, about ¥7 is left as operating profit. Revenue changed +3.4% from the prior year, operating profit -2.7%.
Net margin × asset turnover = ROA; ROA × financial leverage = ROE
Denominators: average assets and average equity. Derived from reported values; ROE is shown only for positive profit and equity.
| Period | Net margin | Asset turnover | ROA | Financial leverage | ROE |
|---|---|---|---|---|---|
| 2022 | 14.5% | 0.69× | 9.9% | 1.39× | 13.8% |
| 2023 | 13.3% | 0.67× | 8.9% | 1.37× | 12.2% |
| 2024 | 6.6% | 0.63× | 4.1% | 1.37× | 5.6% |
| 2025 | 5.5% | 0.65× | 3.6% | 1.42× | 5.1% |
| 2026 | 8.8% | 0.67× | 5.9% | 1.45× | 8.6% |
Financial leverage can raise ROE; a higher value alone does not describe a company's overall condition.
Annual trends in tangible-asset ratios and goodwill balance.
Ratios are derived from reported values. Goodwill is shown only when separately reported; it is not inferred from combined intangible assets. Definition
Track R&D investment and how long operating capital remains tied up before sales turn into cash.
R&D is shown only for years with machine-readable disclosure. Days are estimates using year-end receivables, inventory and payables divided by annual revenue or cost of sales; financial companies are excluded.
| Item | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 42,996 | 43,271 | 40,052 | 40,539 | 41,899 |
| Cost of revenue | 22,431 | 22,765 | 23,328 | 24,027 | 25,723 |
| Gross profit | 20,564 | 20,506 | 16,723 | 16,512 | 16,175 |
| SG&A | 12,184 | 13,049 | 13,345 | 13,512 | 13,255 |
| Operating income | 8,387 | 7,457 | 3,377 | 2,999 | 2,919 |
| Pretax income | 8,482 | 7,592 | 3,503 | 2,991 | 4,834 |
| Income tax | 2,263 | 1,856 | 869 | 763 | 1,125 |
| Net income attributable to owners | 6,218 | 5,736 | 2,634 | 2,228 | 3,708 |
| Operating margin | 19.5% | 17.2% | 8.4% | 7.4% | 7.0% |
Year-end figures from filings. Unreported items are omitted. Interest-bearing debt excludes lease liabilities.
Each bar totals 100% of assets; other is the residual.
| Item | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|
| Cash and equivalents | ¥10.9B | ¥16.1B | ¥11B | ¥7.64B | ¥7.94B |
| Total assets | ¥62.5B | ¥66.3B | ¥61.7B | ¥62.4B | ¥62.7B |
| Net assets | ¥45.8B | ¥49.5B | ¥46B | ¥43.6B | ¥44B |
| Share capital | ¥6.9B | ¥6.9B | ¥6.9B | ¥6.9B | ¥6.9B |
| Property, plant and equipment | ¥15.3B | ¥17.2B | ¥17B | ¥22.1B | ¥23.3B |
| Intangible assets excluding goodwill | ¥1.35B | ¥1.05B | ¥792M | ¥670M | ¥332M |
| Investment securities | ¥3.61B | ¥586M | ¥597M | ¥408M | ¥763M |
| Current assets | ¥37B | ¥39.2B | ¥37.9B | ¥31.5B | ¥32B |
| Current liabilities | ¥12.5B | ¥12.4B | ¥11.4B | ¥14.4B | ¥14.6B |
| Trade payables | ¥4.5B | ¥4.68B | ¥4.65B | ¥5.25B | ¥4.84B |
| Long-term borrowings | — | — | — | — | ¥2.65B |
| Bonds | ¥3B | ¥3B | ¥3B | ¥3B | — |
| Total liabilities | ¥16.7B | ¥16.7B | ¥15.7B | ¥18.8B | ¥18.6B |
| Equity attributable to owners of parent | ¥44.9B | ¥48.7B | ¥44.9B | ¥42.7B | ¥43.4B |
| Retained earnings | ¥33.2B | ¥36.9B | ¥35.8B | ¥34.7B | ¥30.9B |
| Treasury stock | -¥3.13B | -¥3.1B | -¥5.69B | -¥6.76B | -¥2.24B |
EDINET (FSA Japan)
訂正有価証券報告書－第88期(2025/04/01－2026/03/31)
EDINET (FSA Japan)
有価証券報告書－第87期(2024/04/01－2025/03/31)
EDINET (FSA Japan)
有価証券報告書－第86期(2023/04/01－2024/03/31)
EDINET (FSA Japan)
有価証券報告書－第85期(2022/04/01－2023/03/31)
EDINET (FSA Japan)
有価証券報告書－第84期(令和3年4月1日－令和4年3月31日)
EDINET (FSA Japan)
有価証券報告書－第83期(令和2年4月1日－令和3年3月31日)
Extracted from XBRL: 51 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.